Skip to main navigation Skip to search Skip to main content

Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

  • Xavier Mariette*
  • , Olivier Hermine
  • , Pierre Louis Tharaux
  • , Matthieu Resche-Rigon
  • , Raphael Porcher
  • , Philippe Ravaud
  • , Serge Bureau
  • , Maxime Dougados
  • , Annick Tibi
  • , Elie Azoulay
  • , Jacques Cadranel
  • , Joseph Emmerich
  • , Muriel Fartoukh
  • , Bertrand Guidet
  • , Marc Humbert
  • , Karine Lacombe
  • , Matthieu Mahevas
  • , Frédéric Pene
  • , Valérie Pourchet-Martinez
  • , Frédéric Schlemmer
    • Yazdan Yazdanpanah, Gabriel Baron, Elodie Perrodeau, Damien Vanhoye, Cécile Kedzia, Lauren Demerville, Anne Gysembergh-Houal, Alexandre Bourgoin, Sarah Dalibey, Nabil Raked, Lakhdar Mameri, Stéphanie Alary, Samir Hamiria, Thinhinane Bariz, Hala Semri, Dhiaa Meriem Hai, Moustafa Benafla, Mohamed Belloul, Pernelle Vauboin, Saskia Flamand, Claire Pacheco, Anouk Walter-Petrich, Emilia Stan, Souad Benarab, Corine Nyanou, Claire Montlahuc, Lucie Biard, Robin Charreteur, Celine Dupré, Estelle Henry, The CORIMUNO-19 Collaborative group
*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

40 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Nursing and Health Professions

Keyphrases